MyFinsight
Home
Blog
About
Contact
Download
Download image
Net revenue
$76,613K
Gain on sale
transactions, net
$338,315K
Income from operations
$38,241K
Total costs and
expenses
$38,372K
Net income from
discontinued operations...
$351,148K
Other income
(expense), net
-$11,638K
Loss on debt
extinguishment
-$10,286K
Interest expense
$3,484K
Cost of goods sold
$26,755K
Selling, general and
administrative
$11,096K
Research and development
$521K
Net income from
discontinued operations, net...
$351,148K
Net income
$168,024K
Net loss from
continuing operations
-$183,124K
Loss from continuing
operations before income...
-$183,124K
Other income
(expense), net
$7,011K
Toripalimab
$40,836K
Product And Service
Other
$1,336K
Loss from operations
-$181,134K
Interest expense
$9,001K
Net revenue
$42,172K
Total costs and
expenses
$223,306K
Research and development
$108,888K
Selling, general and
administrative
$100,604K
Cost of goods sold
$13,814K
Back
Back
Income Statement
source: myfinsight.com
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)